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Purpose of the study
Data on the hepatic safety of TPV/r comes mostly from clinical trials. The liver tolerability of TPV/r in real life conditions of use could be different. However, there are little data on this issue from clinical cohorts. Because of these, we evaluated the incidence and risk factors of severe liver events among HIV-infected patients treated with drug combinations including TPV/r.
Methods
150 patients were selected because they started a regimen that included TPV/r (500/200 mg BID), and had clinical visits at least every 3 months. Patients who discontinued TPV/r before their first visit were included.
Summary of results
Twelve (8%) individuals developed grade ≥3 transaminase elevation (G ≥ 3TE). Nine (6%) patients discontinued TPV/r due to liver events. Six (8.6%) of 70 HCVcoinfected patients and six (7.5%) of 80 subjects without HCV co-infection developed G ≥ 3TE (p = 1). Liver fibrosis was evaluable in 48 (63%) of 76 individuals with HBV and/or HCV infection. Four (13%) of 30 subjects with moderate-to-severe fibrosis and none of 18 with mild fibrosis showed G ≥ 3TE (p = 0.3). None of nine patients with cirrhosis showed G ≥ 3TE.
Conclusion
Liver tolerability of TPV/r was generally good in a cohort of patients with a high proportion of HCV co-infection, including subjects with advanced fibrosis. Monitoring of liver enzymes was not different for co-infected patients. Thus, more frequent blood testing does not seem warranted for these patients.
